ArticleInternational journal of molecular medicine2019
TROP2 increases growth and metastasis of human oral squamous cell carcinoma through activation of the PI3K/Akt signaling pathway.
Article in International journal of molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 38 citations in OpenAlex.
- Loss of IL1RA promotes prostate cancer growth and metastasis by activating Akt signaling pathway.PloS one · 2026Article
- Trophoblast cell-surface antigen 2 expression in digestive neoplasms: a promising target for antibody-drug conjugates.The oncologist · 2025Article
- Engineered Nanobody-Bearing Extracellular Vesicles Enable Precision Trop2 Knockdown in Resistant Breast Cancer.Pharmaceutics · 2025Article
- Emerging Concepts in Immuno-Oncology: Insights from Natural Language Processing-Driven Co-Occurrence Analysis.ACS omega · 2025Review
- Dysregulated PI3K/AKT signaling in oral squamous cell carcinoma: The tumor microenvironment and epigenetic modifiers as key drivers.Oncology research · 2025Review
- The complex interplay of TROP2 and PD-L1 in immune regulation and drug resistance in lung cancer.American journal of cancer research · 2025Article
- Trop2 Expression in Correlation to the Molecular Subtype in Vulvar Squamous Cell Carcinomas.Pathobiology : journal of immunopathology, molecular and cellular biology · 2025Article
- Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook.Molecular pharmaceutics · 2024Review
- Novel Anti-Trop2 Nanobodies Disrupt Receptor Dimerization and Inhibit Tumor Cell Growth.Pharmaceutics · 2024Article
- ImmunoPET imaging of Trop2 in patients with solid tumours.EMBO molecular medicine · 2024Article
- Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back.Frontiers in immunology · 2024Review
- An assembly of TROP2-mediated signaling events.Journal of cell communication and signaling · 2023Article
- Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan.NPJ breast cancer · 2023Article
- Propionate-producing Veillonella parvula regulates the malignant properties of tumor cells of OSCC.Medical oncology (Northwood, London, England) · 2023Article
- Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements.Frontiers in oncology · 2023Review
- TROP2 is a Good Indicator for Infiltrative Nature of Carcinoma Rather than Diagnosing Malignancy in Thyroid.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022Article
- Role of PI3K/AKT pathway in squamous cell carcinoma with an especial focus on head and neck cancers.Cancer cell international · 2022Review
- Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer.Breast cancer research and treatment · 2022Article
- TACSTD2 upregulation is an early reaction to lung infection.Scientific reports · 2022Article
- Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.American journal of cancer research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most malignant neoplasms of the oral cavity are oral squamous cell carcinoma (OSCC), which is a type of highly malignant tumor with a propensity for forming distant metastases. Trophoblast cell surface antigen 2 (TROP2) is a transmembrane protein that is overexpressed in several types of tumor cells, although its role and regulatory mechanism in OSCC have not been determined. The aim of the present study was to examine the effects of TROP2 in human OSCC cell lines. The present study demonstrated that TROP2 protein expression was upregulated in OSCC cell lines. Transfection of short hairpin RNA (shRNA) targeting TROP2 (sh‑TROP2) reduced cell proliferation, migration and invasion of OSCC cell lines, whereas overexpression of TROP2 increased proliferation, migration and invasion. sh‑TROP2 transfection in OSCC cell lines inhibited tumor growth in OSCC mouse models. Furthermore, TROP2 expression activated the phosphoinositide 3‑kinase (PI3K)/Akt signaling pathway in human OSCC cells. These results suggest that TROP2 induces cell growth, migration and invasion through activation of the PI3K/Akt signaling pathway in OSCC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.